Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric study

C. De Simone, F. Albertini, M. Almaviva, G. Angarano, F. Chiodo, P. Costigliola, S. Delia, A. Ferlini, F. Gritti, G. Mazzarello, F. Milazzo, M. Montroni, P. Narciso, G. Pastore, E. Raise, G. Santini, F. Sorice, A. Terragna, G. Visco, V. Vullo

Research output: Contribution to journalArticlepeer-review

Abstract

Inosine-pranobex (methisoprinol, isoprinosine; INPX) is the p-acetamidobenzoic salt of N,N-dimethylamino-2-propanol and inosine in a 3:1 molar ratio. In early studies, INPX was found to partially inhibit human immunodeficiency virus (HIV) and to increase the immunocompetence of HIV-infected subjects in vitro. We report the results of a randomised, multicentric clinical trial carried out on 553 HIV+ patients. 261 individuals were treated with INPX (two 500 mg tablets every 6 h for 3 months) and the remaining 292 constituted the untreated control group. INPX treatment was associated with a slightly improved clinical condition or with a trend in that direction, as compared to the untreated group. A preservation of the CD4/CD8 cell ratio values, a decrease in the CD8+ cells and an increase in the Leu 2-7+ cell number better than in the untreated individuals was also observed in the patients taking INPX. No serious or adverse effects of INPX have been observed.

Original languageEnglish
Pages (from-to)63-67
Number of pages5
JournalMedical Oncology and Tumor Pharmacotherapy
Volume6
Issue number1
DOIs
Publication statusPublished - Mar 1989

Keywords

  • AIDS
  • Immunotherapy
  • Isoprinosine

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Oncology

Fingerprint

Dive into the research topics of 'Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric study'. Together they form a unique fingerprint.

Cite this